Barclays Raises Cooper Companies (NASDAQ:COO) Price Target to $103.00

Cooper Companies (NASDAQ:COO) had its target price upped by Barclays from $98.00 to $103.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has an “overweight” rating on the medical device company’s stock. Barclays‘s price objective would indicate a potential upside of 33.68% from the stock’s current price.

A number of other brokerages have also recently issued reports on COO. Citigroup reiterated a “neutral” rating and issued a $88.00 target price (up from $72.00) on shares of Cooper Companies in a report on Monday, December 8th. Wells Fargo & Company upped their target price on shares of Cooper Companies from $72.00 to $82.00 and gave the stock an “equal weight” rating in a report on Friday, December 5th. Morgan Stanley raised their price target on shares of Cooper Companies from $76.00 to $83.00 and gave the company an “equal weight” rating in a research report on Monday, December 8th. Wall Street Zen raised Cooper Companies from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. Finally, The Goldman Sachs Group restated a “sell” rating and issued a $73.00 target price on shares of Cooper Companies in a report on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $90.86.

Cooper Companies Stock Down 3.9%

Shares of COO stock traded down $3.15 on Friday, reaching $77.05. 1,462,397 shares of the company were exchanged, compared to its average volume of 1,977,256. The company has a market cap of $15.03 billion, a price-to-earnings ratio of 40.98, a PEG ratio of 2.34 and a beta of 1.02. The company has a 50-day moving average of $82.23 and a 200-day moving average of $75.95. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.89 and a quick ratio of 1.13. Cooper Companies has a one year low of $61.78 and a one year high of $89.83.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Thursday, March 5th. The medical device company reported $1.10 EPS for the quarter, beating analysts’ consensus estimates of $1.03 by $0.07. Cooper Companies had a return on equity of 10.02% and a net margin of 9.16%.The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same period in the previous year, the company posted $0.92 EPS. The firm’s revenue was up 6.2% compared to the same quarter last year. Cooper Companies has set its Q2 2026 guidance at 4.580-4.660 EPS. Analysts anticipate that Cooper Companies will post 3.98 earnings per share for the current year.

Insider Buying and Selling at Cooper Companies

In other Cooper Companies news, Director Lawrence Erik Kurzius acquired 2,000 shares of the business’s stock in a transaction on Wednesday, December 17th. The shares were acquired at an average price of $82.50 per share, with a total value of $165,000.00. Following the completion of the transaction, the director owned 7,777 shares in the company, valued at approximately $641,602.50. This trade represents a 34.62% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Cynthia L. Lucchese bought 1,784 shares of the firm’s stock in a transaction dated Monday, December 22nd. The shares were acquired at an average cost of $84.06 per share, with a total value of $149,963.04. Following the completion of the transaction, the director owned 9,445 shares in the company, valued at approximately $793,946.70. The trade was a 23.29% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased a total of 16,014 shares of company stock valued at $1,304,416 in the last ninety days. 2.08% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Buckhead Capital Management LLC lifted its holdings in Cooper Companies by 14.3% during the third quarter. Buckhead Capital Management LLC now owns 58,930 shares of the medical device company’s stock valued at $4,040,000 after purchasing an additional 7,368 shares during the last quarter. First American Bank bought a new stake in shares of Cooper Companies in the third quarter valued at approximately $1,646,000. Rakuten Investment Management Inc. purchased a new stake in shares of Cooper Companies during the 3rd quarter valued at approximately $11,341,000. Amundi boosted its holdings in Cooper Companies by 35.5% in the 2nd quarter. Amundi now owns 1,331,480 shares of the medical device company’s stock worth $97,225,000 after buying an additional 348,652 shares during the period. Finally, Massachusetts Financial Services Co. MA grew its stake in Cooper Companies by 96.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,099,750 shares of the medical device company’s stock valued at $212,519,000 after buying an additional 1,525,693 shares in the last quarter. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

Cooper Companies News Roundup

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Q1 results beat and company raised guidance — Cooper reported $1.10 EPS (above consensus) and ~6.2% revenue growth; management raised EPS and free‑cash‑flow guidance for 2026, highlighting momentum in MyDay and MiSight contact lenses. CooperCompanies Announces First-Quarter 2026 Results
• Positive Sentiment: Analyst upgrade and price‑target lift — Needham raised its price target to $101 and kept a Buy rating, providing explicit upside catalysts tied to product momentum and guidance. Benzinga
• Positive Sentiment: Insider buying and operational metrics — Recent reported insider purchases and improved operating leverage (higher operating margin, stronger cash from ops) support confidence in execution. The Cooper Companies (COO) Stock Falls on Q1 2026 Earnings
• Neutral Sentiment: Product R&D / clinical messaging at NCC 2026 — CooperVision highlighted research supporting long‑term comfort for contact lens wearers, which helps the narrative but is a longer‑term commercial story. NCC 2026: CooperVision Research Supports a Lifetime of Clear, Comfortable Contact Lens Wear
• Neutral Sentiment: Strategic review flagged by company/press coverage — Reports note a strategic review is in focus; this can be neutral-to-positive depending on outcomes (asset sales, portfolio moves). Cooper Companies earnings up next: Strategic review in focus
• Negative Sentiment: Analyst caution on core vision growth — Morgan Stanley kept a Hold and $83 target, citing sluggish core CooperVision growth that could limit upside despite fertility and specialty lens gains. Cooper Companies: Solid Earnings and Fertility Recovery Offset by Sluggish Core Vision Growth, Warranting a Hold Rating
• Negative Sentiment: Valuation and mixed top‑line reads — COO trades at a premium multiple (P/E ~42.7) and revenue growth is modest; if CooperVision growth stays tepid, valuation could cap near‑term gains.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.